Literature DB >> 15735048

Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation.

Kui Shin Voo1, Guangyong Peng, Zhong Guo, Tihui Fu, Yanchun Li, Lori Frappier, Rong-Fu Wang.   

Abstract

CD4(+) helper and regulatory T (Treg) cells play important but opposing roles in regulating host immune responses against cancer and other diseases. However, very little is known about the antigen specificity of CD4(+) Treg cells. Here we describe the generation of a panel of EBV-encoded nuclear antigen 1 (EBNA1)-specific CD4(+) T-cell lines and clones that recognize naturally processed EBNA1-P(607-619) and -P(561-573) peptides in the context of HLA-DQ2 and HLA-DR11, -DR12, and -DR13 molecules, respectively. Phenotypic and functional analyses of these CD4(+) T cells revealed that they represent EBNA1-specific CD4(+) T helper as well as Treg cells. CD4(+) Treg cells do not secrete interleukin (IL)-10 and transforming growth factor beta cytokines but express CD25, the glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), and Forkhead Box P3 (Foxp3), and are capable of suppressing the proliferative responses of naive CD4(+) and CD8(+) T cells to stimulation with mitogenic anti-CD3 antibody. The suppressive activity of these CD4(+) Treg cells is mediated via cell-cell contact or in part by a cytokine-dependent manner. Importantly, these Treg cells suppress IL-2 secretion by CD4(+) effector T cells specific for either EBNA1 or a melanoma antigen, suggesting that these CD4(+) Treg cells induce immune suppression. These observations suggest that the success of peptide-based vaccines against EBV-associated cancer and other diseases may likely depend upon our ability to identify antigens/peptides that preferentially activate helper T cells and/or to design strategies to regulate the balance between CD4(+) helper and Treg cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735048     DOI: 10.1158/0008-5472.CAN-04-2552

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Adoptive immunotherapy for Hodgkin's lymphoma.

Authors:  Alana A Kennedy-Nasser; Catherine M Bollard; Cliona M Rooney
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 2.  Natural regulatory T cells and persistent viral infection.

Authors:  Shuo Li; Eric J Gowans; Claire Chougnet; Magdalena Plebanski; Ulf Dittmer
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

Review 3.  Viral manipulation of the host immune response.

Authors:  Allison Christiaansen; Steven M Varga; Juliet V Spencer
Journal:  Curr Opin Immunol       Date:  2015-07-10       Impact factor: 7.486

Review 4.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

5.  Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire.

Authors:  Julien Fourcade; Zhaojun Sun; Pavol Kudela; Bratislav Janjic; John M Kirkwood; Talal El-Hafnawy; Hassane M Zarour
Journal:  J Immunol       Date:  2010-05-10       Impact factor: 5.422

Review 6.  CD8+ Tregs in lupus, autoimmunity, and beyond.

Authors:  Ravi K Dinesh; Brian J Skaggs; Antonio La Cava; Bevra H Hahn; Ram Pyare Singh
Journal:  Autoimmun Rev       Date:  2010-04-10       Impact factor: 9.754

7.  DRB1*12:01 presents a unique subset of epitopes by preferring aromatics in pocket 9.

Authors:  I-Ting Chow; Eddie A James; Venus Tan; Antonis K Moustakas; George K Papadopoulos; William W Kwok
Journal:  Mol Immunol       Date:  2011-12-23       Impact factor: 4.407

8.  Development of virus-specific CD4+ and CD8+ regulatory T cells induced by human herpesvirus 6 infection.

Authors:  Fang Wang; Jing Chi; Guangyong Peng; Feng Zhou; Jinfeng Wang; Lingyun Li; Dongju Feng; Fangyi Xie; Bin Gu; Jian Qin; Yun Chen; Kun Yao
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

9.  Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma.

Authors:  Mark Fogg; John R Murphy; Jochen Lorch; Marshall Posner; Fred Wang
Journal:  Virology       Date:  2013-04-17       Impact factor: 3.616

10.  Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.

Authors:  Mark H Fogg; Lori J Wirth; Marshall Posner; Fred Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.